H
Develops off-the-shelf cell therapies using stem cell-based regenerative medicine to treat late-stage liver disease, providing a scalable alternative to liver transplantation. This approach addresses the critical shortage of donor organs, with over 200,000 patients annually facing end-stage liver failure in the U.S. alone.
Updated 20 months ago
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVLBSHSSFunding rounds are not available yet.
Founders
Product
Features
- Develops off-the-shelf cell therapies using stem cell-based regenerative medicine to treat late-stage liver disease, providing a scalable alternative to liver transplantation. This approach addresses the critical shortage of donor organs, with over 200,000 patients annually facing end-stage liver failure in the U.S. alone.